Transgenomic sells Wave System to Genzyme | GenomeWeb

NEW YORK, April 23 – Transgenomic has sold its Wave genetic analysis system to biotechnology giant Genzyme, the companies said Monday.

Genzyme will use the system in its research on genetic mutations that cause or are associated with hereditary diseases such as lysosomal storage disorders and some cancers. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.